SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-140010
Filing Date
2023-05-10
Accepted
2023-05-10 07:09:00
Documents
14
Period of Report
2023-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d459099d8k.htm   iXBRL 8-K 24176
2 EX-99.1 d459099dex991.htm EX-99.1 31091
6 GRAPHIC g459099g27q68.jpg GRAPHIC 11548
  Complete submission text file 0001193125-23-140010.txt   197287

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tcrt-20230510.xsd EX-101.SCH 2839
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrt-20230510_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrt-20230510_pre.xml EX-101.PRE 10805
8 EXTRACTED XBRL INSTANCE DOCUMENT d459099d8k_htm.xml XML 3229
Mailing Address 8030 EL RIO STREET HOUSTON TX 77054
Business Address 8030 EL RIO STREET HOUSTON TX 77054 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

IRS No.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 23904305
SIC: 2834 Pharmaceutical Preparations